Stockscreener 앱 받기
94.37
0.22%
-0.21
시간 외 거래:
94.37
전일 마감가:
$94.58
열려 있는:
$94.48
하루 거래량:
3.44M
Relative Volume:
1.91
시가총액:
$7.14B
수익:
$35.93M
순이익/손실:
$-244.56M
주가수익비율:
-23.89
EPS:
-3.95
순현금흐름:
$-157.31M
1주 성능:
+0.08%
1개월 성능:
+40.58%
6개월 성능:
+144.36%
1년 성능:
+79.34%
1일 변동 폭
$94.33
$94.63
1주일 범위
$94.15
$94.63
52주 변동 폭
$33.19
$94.63
Merus N V Stock (MRUS) Company Profile
명칭
Merus N V
전화
31 030 253 8800
주소
YALELAAN 62, 3584 CM UTRECHT
MRUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
94.37 | 7.17B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-08-25 | 개시 | Alliance Global Partners | Buy |
| 2025-02-13 | 개시 | Piper Sandler | Overweight |
| 2025-02-07 | 개시 | Wells Fargo | Overweight |
| 2024-11-21 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-03-28 | 개시 | Truist | Buy |
| 2024-03-04 | 재확인 | Needham | Buy |
| 2023-11-02 | 개시 | Canaccord Genuity | Buy |
| 2023-08-21 | 개시 | TD Cowen | Outperform |
| 2022-08-02 | 개시 | Stifel | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Needham | Buy |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-06-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-08 | 개시 | William Blair | Outperform |
| 2021-03-16 | 개시 | SVB Leerink | Outperform |
| 2020-06-26 | 개시 | H.C. Wainwright | Buy |
| 2020-05-27 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | 재개 | Guggenheim | Buy |
| 2019-06-28 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 재개 | Guggenheim | Buy |
| 2019-04-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-03-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-12-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2016-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-06-13 | 개시 | Citigroup | Buy |
| 2016-06-13 | 개시 | Guggenheim | Buy |
| 2016-06-13 | 개시 | Wedbush | Outperform |
모두보기
Merus N V 주식(MRUS)의 최신 뉴스
Merus N.V. announces proposed public offering of common shares - MSN
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
Merus (NASDAQ:MRUS) Hits New 12-Month HighHere's Why - MarketBeat
Merus (NASDAQ:MRUS) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Automated trading signals detected on Merus N.V.July 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Is Merus N.V. (2GH) stock safe for risk averse investorsWall Street Watch & Accurate Entry/Exit Alerts - newser.com
What margin trends mean for Merus N.V. stockNew Guidance & Daily Price Action Insights - newser.com
Is Merus NV a good long term investmentTrading Psychology Tips & Market Monitoring and Alerts - earlytimes.in
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, ODP, PRO, MRUS on Behalf of Shareholders - GlobeNewswire Inc.
Merus NV stock hits all-time high at 94.56 USD By Investing.com - Investing.com Nigeria
Merus NV stock hits all-time high at 94.56 USD - Investing.com
Will Merus N.V. stock see PE expansion2025 Short Interest & Real-Time Volume Spike Alerts - newser.com
Why Merus N.V. (2GH) stock could outperform next yearJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise By Investing.com - Investing.com South Africa
Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise - Investing.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Oklahoma City NewsThe Oklahoman - FinancialContent
Merus (NASDAQ:MRUS) Downgraded by Leerink Partnrs to "Hold" - MarketBeat
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - sharewise.com
Truist Securities raises Genmab stock price target to $49 on Merus acquisition - Investing.com
Is Merus N.V. building a consolidation baseQuarterly Profit Review & Short-Term High Return Strategies - newser.com
Leerink Partners Downgrades Merus to Market Perform From Outperform, Adjusts PT to $97 From $95 - MarketScreener
MRUS Downgraded to Market Perform by Leerink Partners with Raise - GuruFocus
What MACD signals say about Merus N.V.Profit Target & Consistent Profit Alerts - newser.com
Leerink Partners downgrades Merus stock to Market Perform on Genmab deal - Investing.com
What’s the recovery path for long term holders of Merus N.V.2025 Major Catalysts & Reliable Entry Point Trade Alerts - newser.com
How big funds are accumulating Merus N.V. (2GH) stockRecession Risk & Verified Entry Point Detection - newser.com
Relative strength of Merus N.V. in sector analysisJuly 2025 Recap & Fast Entry Momentum Alerts - newser.com
Will Merus N.V. (2GH) stock maintain strong growth2025 Institutional Moves & Community Verified Swing Trade Signals - newser.com
Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion - MSN
Genmab acquires Merus for $97 per share in cash or $8B - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRU - GuruFocus
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, VECO on Behalf of Shareholders - cnhinews.com
Truist raises Genmab stock price target to $49 on Merus acquisition - Investing.com
Custom strategy builders for tracking Merus N.V.Market Sentiment Summary & Daily Profit Focused Screening - newser.com
Will Merus N.V. stock continue upward momentum2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Will Merus N.V. see short term momentumWeekly Profit Summary & Real-Time Buy Signal Alerts - newser.com
Genmab to acquire Merus for $ 8 billion - Indian Pharma Post
Merus N V (MRUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Merus N V 주식 (MRUS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
5.74%
자본화:
|
볼륨(24시간):